Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:EMHNYSE:EVRCVE:WHY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsEVREvercore$238.55+1.4%$206.12$148.63▼$324.06$9.34B1.39472,179 shs134,148 shsWHYWest High Yield (W.H.Y.) ResourcesC$0.53-3.6%C$0.33C$0.18▼C$0.56C$53.66M1.74103,567 shs204,737 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%EVREvercore-0.20%+1.62%+11.12%+12.41%+20.88%WHYWest High Yield (W.H.Y.) Resources+11.11%+26.44%+86.44%+107.55%+92.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEVREvercore4.4782 of 5 stars2.35.04.21.82.31.71.9WHYWest High Yield (W.H.Y.) ResourcesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMHEmerald Health Therapeutics 0.00N/AN/AN/AEVREvercore 2.57Moderate Buy$231.00-3.16% DownsideWHYWest High Yield (W.H.Y.) Resources 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EVR, G1A, WHY, and EMH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025EVREvercoreThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$234.00 ➝ $266.005/12/2025EVREvercoreKeefe, Bruyette & WoodsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$238.00 ➝ $257.005/1/2025EVREvercoreMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$173.00 ➝ $175.005/1/2025EVREvercoreWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$180.00 ➝ $194.004/8/2025EVREvercoreWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$199.00 ➝ $180.004/8/2025EVREvercoreJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Market Outperform$230.00 ➝ $230.004/8/2025EVREvercoreCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$230.004/7/2025EVREvercoreMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$306.00 ➝ $173.004/2/2025EVREvercoreThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$281.00 ➝ $252.003/14/2025EVREvercoreThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$321.00 ➝ $281.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64EVREvercore$3.09B3.02$10.74 per share22.22$47.19 per share5.06WHYWest High Yield (W.H.Y.) ResourcesN/AN/AC$0.02 per share24.21C($0.07) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/AEVREvercore$378.28M$10.4526.3610.67N/A12.64%24.19%12.61%7/23/2025 (Estimated)WHYWest High Yield (W.H.Y.) Resources-C$3.93M-C$0.04N/A∞N/AN/A69.71%-81.18%N/ALatest EVR, G1A, WHY, and EMH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025EVREvercore$1.60$3.49+$1.89$3.48$704.54 million$699.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AEVREvercore$3.361.41%+6.04%32.15%18 YearsWHYWest High Yield (W.H.Y.) ResourcesN/A4.62%N/AN/AN/ALatest EVR, G1A, WHY, and EMH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2025EVREvercorequarterly$0.841.69%5/30/20255/30/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMHEmerald Health Therapeutics35.452.972.61EVREvercore0.192.981.43WHYWest High Yield (W.H.Y.) Resources-87.980.030.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMHEmerald Health TherapeuticsN/AEVREvercore86.23%WHYWest High Yield (W.H.Y.) ResourcesN/AInsider OwnershipCompanyInsider OwnershipEMHEmerald Health TherapeuticsN/AEVREvercore6.08%WHYWest High Yield (W.H.Y.) Resources26.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableEVREvercore2,12039.12 million34.91 millionOptionableWHYWest High Yield (W.H.Y.) ResourcesN/A101.24 millionN/ANot OptionableEVR, G1A, WHY, and EMH HeadlinesRecent News About These CompaniesWest High Yield (W.H.Y.) Resources Ltd. Announces Proceeds from Exercise of WarrantsJune 2 at 8:36 PM | finance.yahoo.comWest High Yield Resources Gains CAD$15,000 from Warrant ExerciseJune 2 at 6:09 PM | tipranks.comWest High Yield (W.H.Y.) Resources Ltd. Fully Endorses Draft Minister's Designation Report on the Record Ridge Critical Minerals ProjectMay 29, 2025 | finance.yahoo.comWHY pushes back against statements made by Record Ridge mining development review committeeApril 7, 2025 | castanet.netWest High Yield Resources Ltd.March 22, 2025 | goldinvest.deWest High Yield Gears Up for 2025 Production at Record Ridge Magnesium ProjectMarch 12, 2025 | msn.comWest High Yield (W.H.Y.) Resources Ltd. Announces Private Placement Offering, Loan Amendments, and World-First Magnesium Battery BreakthroughFebruary 20, 2025 | finance.yahoo.comWest High Yield (W.H.Y.) Resources Ltd. (WHYRF)January 25, 2025 | ca.finance.yahoo.comWest High Yield (W.H.Y.) Resources Ltd. Announces Proceeds from Exercise of OptionsNovember 23, 2024 | finance.yahoo.comWest High Yield (W.H.Y.) Resources Ltd. Announces Final Closings of Oversubscribed Private Placement and Shares-for-Debt TransactionsNovember 15, 2024 | finance.yahoo.comWest High Yield (W.H.Y.) Resources Ltd. Announces Extension of Current Private PlacementOctober 12, 2024 | finance.yahoo.comWest High Yield (W.H.Y.) Resources Ltd. Announces Second Tranche Closing of Private Placement and Debt for Shares TransactionOctober 9, 2024 | finance.yahoo.comWest High Yield (W.H.Y.) Resources Ltd. Announces Amended Permit SubmissionSeptember 19, 2024 | msn.comWest High Yield (W.H.Y.) Resources Ltd. Announces Mine Permit Update, Corporate Update, and Private Placement OfferingAugust 29, 2024 | finanznachrichten.deH World: Q3 Outlook And Shareholder Yield Are Key Investment ConsiderationsAugust 26, 2024 | seekingalpha.comWest High Yield (W.H.Y.) Resources Ltd. Outlines Next Steps for the Record Ridge Magnesium Project Mine PermitAugust 15, 2024 | finance.yahoo.comHow the state government plans to aid West Virginia farmers suffering from droughtAugust 13, 2024 | msn.comWest High Yield (W.H.Y.) Resources Ltd. Announces Final Closing of Oversubscribed Private Placement and Signing of Sponsorship AgreementMay 10, 2024 | finance.yahoo.comWest High Yield (W.H.Y.) Resources Ltd. Announces Stock Option GrantMarch 27, 2024 | finance.yahoo.comStock Market Highlights: Nifty breaches 20-DEMA, trendline support. What traders should do on Thursday expiryMarch 15, 2024 | economictimes.indiatimes.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Super Micro Computer's Upside Could Trigger a Short SqueezeBy Gabriel Osorio-Mazilli | June 3, 2025View Why Super Micro Computer's Upside Could Trigger a Short SqueezeWhy SoundHound Could Be a Short Squeeze in the MakingBy Gabriel Osorio-Mazilli | June 2, 2025View Why SoundHound Could Be a Short Squeeze in the MakingWhy Amazon May Never Dip Below $200 AgainBy Sam Quirke | May 13, 2025View Why Amazon May Never Dip Below $200 AgainTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s WhyBy Thomas Hughes | May 29, 2025View NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s WhyEVR, G1A, WHY, and EMH Company DescriptionsEmerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.Evercore NYSE:EVR$238.55 +3.28 (+1.39%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. It operates through two segments, Investment Banking & Equities, and Investment Management. The Investment Banking & Equities segment offers strategic advisory services, such as mergers, and acquisitions, strategic, defense, and shareholder advisory, special committee assignments, and real estate strategic advisory; private capital advisory and fundraising, market risk management and hedging, private capital markets and debt advisory, liability management and restructuring, and equity capital markets execution and advisory services; and research, sales, and trading professionals services on a content-led platform to its institutional investor clients. The Investment Management segment provides wealth management services to high-net-worth individuals, foundations, and endowments; and manages financial assets for institutional investors. The company was formerly known as Evercore Partners Inc. and changed its name to Evercore Inc. in August 2017. Evercore Inc. was founded in 1995 and is headquartered in New York, New York.West High Yield (W.H.Y.) Resources CVE:WHYC$0.53 -0.02 (-3.64%) As of 12:57 PM EasternWest High Yield (W.H.Y.) Resources Ltd. engages in the acquisition, exploration, and development of mineral properties in British Columbia, Canada. The company explores for gold, nickel, silica, and magnesium deposits. Its flagship property is its 100% owned Record Ridge property comprising 29 contiguous mineral claims, eight crown-granted claims, and one privately owned claim covering an area of 8,972 hectares located near southwest of the city of Rossland, British Columbia. The company was incorporated in 2003 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
